Bayer Enters AI Deal to Tap U.K. Health Data for Heart Medicines

Bayer AG entered a two-year agreement to use artificial intelligence to hunt for heart treatments using Sensyne Health Plc’s trove of U.K. health records.

Sensyne’s partners, a group of National Health Service trusts, will receive 4% of all proceeds from the 5-million pound ($5.6 million) deal, the Oxford, England-based company said July 31 in a statement.

Sensyne is collaborating with NHS divisions to put patient information into a database that companies and entrepreneurs can analyze to develop new products and treatment approaches that will benefit the agency’s patients. The Bayer deal, focused on cardiovascular disease, is the first announced so ...